Success Metrics

Active Trials
1(20%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
1
20%
Ph not_applicable
2
40%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Other(3)

Detailed Status

unknown3
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
N/A2 (40.0%)

Trials by Status

recruiting120%
unknown360%
not_yet_recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_2

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

NCT07188610
not_yet_recruitingnot_applicable

Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases

NCT06871644
unknownphase_1

PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

NCT05170568
unknownnot_applicable

CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

NCT04785833
unknownphase_1

CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

NCT04480788

Clinical Trials (5)

Showing 5 of 5 trials
NCT07188610Phase 2

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

Recruiting
NCT06871644Not Applicable

Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases

Not Yet Recruiting
NCT05170568Phase 1

PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

Unknown
NCT04785833Not Applicable

CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

Unknown
NCT04480788Phase 1

CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

Unknown

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5